{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:15:17Z","timestamp":1774991717882,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jfma.2022.10.012","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T07:28:13Z","timestamp":1668238093000},"page":"221-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term treatment outcomes\/toxicities of definite chemoradiotherapy (intensity-modulated radiation therapy) for early-stage \u201cbulky\u201d cervical cancer and survival impact of histological subtype"],"prefix":"10.1016","volume":"122","author":[{"given":"He-Yuan","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hsing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11 Suppl 2","key":"10.1016\/j.jfma.2022.10.012_bib1","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1111\/IGC.0b013e3181f7b241","article-title":"Modern radiotherapy and cervical cancer","volume":"20","author":"Powell","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jfma.2022.10.012_bib2","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170398","article-title":"Cervical cancer treated with reduced-volume intensity-modulated radiation therapy base on Sedlis criteria (NCCN VS RTOG)","volume":"91","author":"Luo","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.jfma.2022.10.012_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ygyno.2011.12.432","article-title":"Intensity-modulated radiation therapy for advanced cervical cancer: a comparison of dosimetric and clinical outcomes with conventional radiotherapy","volume":"125","author":"Du","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jfma.2022.10.012_bib4","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ijrobp.2013.06.2059","article-title":"Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study","volume":"87","author":"Gandhi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jfma.2022.10.012_bib5","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.canrad.2016.05.011","article-title":"Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: a randomized prospective study","volume":"20","author":"Naik","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.jfma.2022.10.012_bib6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ijrobp.2016.11.027","article-title":"Bone Marrow-sparing intensity modulated radiation therapy with concurrent cisplatin for stage IB-IVA cervical cancer: an international multicenter phase II clinical trial (INTERTECC-2)","volume":"97","author":"Mell","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.012_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2011.03.034","article-title":"Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer","volume":"122","author":"Chen","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.jfma.2022.10.012_bib8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/ijgc-2020-001412","article-title":"Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer","volume":"30","author":"Contreras","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jfma.2022.10.012_bib9","doi-asserted-by":"crossref","first-page":"2538e2544","DOI":"10.1200\/JCO.2017.77.4273","article-title":"Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG oncology-RTOG 1203","volume":"36","author":"Klopp","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2022.10.012_bib10","doi-asserted-by":"crossref","first-page":"S1eS2","DOI":"10.1016\/j.ijrobp.2020.07.2069","article-title":"Phase III randomized trial of postoperative adjuvant conventional radiation (3DCRT) versus image guided intensity modulated radiotherapy (IG-IMRT) in cervical cancer (PARCER): final analysis","volume":"108","author":"Chopra","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"33","key":"10.1016\/j.jfma.2022.10.012_bib11","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1200\/JCO.20.02530","article-title":"Late toxicity after adjuvant conventional radiation versus image-guided intensity-modulated radiotherapy for cervical cancer (PARCER): a randomized controlled trial","volume":"39","author":"Chopra","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.012_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13014-018-1126-7","article-title":"Intensity-modulated radiation therapy for definitive treatment of cervical cancer: a meta-analysis","volume":"13","author":"Lin","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.jfma.2022.10.012_bib13","doi-asserted-by":"crossref","first-page":"1855e1861","DOI":"10.1136\/ijgc-2020-001973","article-title":"Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB-IVA: oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study","volume":"30","author":"Marnitz","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jfma.2022.10.012_bib14","first-page":"XC09eXC13","article-title":"Long term clinical outcome and late toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma","volume":"13","author":"Gandhi","year":"2019","journal-title":"J Clin Diag Res"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.012_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jfma.2012.10.021","article-title":"The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy","volume":"114","author":"Chen","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2022.10.012_bib16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fonc.2019.00520","article-title":"Long-term survival and late toxicity associated with pelvic intensity modulated radiation therapy (IMRT) for cervical cancer involving CT-based positive lymph nodes","volume":"9","author":"Lei","year":"2019","journal-title":"Front Oncol"},{"issue":"1 Pt 1","key":"10.1016\/j.jfma.2022.10.012_bib17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jfma.2018.01.015","article-title":"Definite chemoradiotherapy is a competent treatment option in FIGO stage IB2 cervical cancer compared with radical surgery +\/- neoadjuvant chemotherapy","volume":"118","author":"Hsieh","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2022.10.012_bib18","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM199904153401501","article-title":"Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer","volume":"340","author":"Morris","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2022.10.012_bib19","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","article-title":"Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer","volume":"340","author":"Rose","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2022.10.012_bib20","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1200\/JCO.1999.17.5.1339","article-title":"Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study","volume":"17","author":"Whitney","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2022.10.012_bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1471-2407-7-164","article-title":"Prognostic value of histopathology and trends in cervical cancer: a SEER population study","volume":"7","author":"Vinh-Hung","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jfma.2022.10.012_bib22","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ygyno.2014.01.043","article-title":"Comparison of clinical outcomes of adenocarcinoma and adenosquamous carcinoma in uterine cervical cancer patients receiving surgical resection followed by radiotherapy: a multicenter retrospective study (KROG 13-10)","volume":"132","author":"Noh","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jfma.2022.10.012_bib23","first-page":"2199","article-title":"Postoperative radiotherapy for uterine cervical cancer: impact of lymph node and histological type on survival","volume":"33","author":"Kasuya","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jfma.2022.10.012_bib24","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/aogs.12383","article-title":"Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma\/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy","volume":"93","author":"Chen","year":"2014","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.jfma.2022.10.012_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/jjco\/hyw145","article-title":"Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors","volume":"47","author":"Seki","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jfma.2022.10.012_bib26","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.3802\/jgo.2017.28.e19","article-title":"Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma\/adenosquamous carcinoma versus squamous cell carcinoma","volume":"28","author":"Yokoi","year":"2017","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.jfma.2022.10.012_bib27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ygyno.2012.06.021","article-title":"Impact of histological subtype on survival of patients with surgically-treated stageIA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma","volume":"127","author":"Mabuchi","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jfma.2022.10.012_bib28","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ygyno.2012.01.034","article-title":"Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer","volume":"125","author":"Katanyoo","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jfma.2022.10.012_bib29","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ijrobp.2010.02.009","article-title":"Long-term outcome and prognostic factors for adenocarcinoma\/adenosquamous carcinoma of cervix after definitive radiotherapy","volume":"80","author":"Huang","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jfma.2022.10.012_bib30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1006\/gyno.1999.5387","article-title":"A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study","volume":"73","author":"Sedlis","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jfma.2022.10.012_bib31","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00404-015-3701-6","article-title":"Prognostic factors affecting cervical adenocarcinoma: 10 years experience in a single institution","volume":"292","author":"Khalil","year":"2015","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.jfma.2022.10.012_bib32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.suronc.2016.05.028","article-title":"Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma\/adenosquamous carcinoma after primary radical surgery: a Taiwanese Gynecologic Oncology Group (TGOG) study","volume":"25","author":"Twu","year":"2016","journal-title":"Surg Oncol"},{"key":"10.1016\/j.jfma.2022.10.012_bib33","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/sim.5705","article-title":"The performance of different propensity score methods for estimating marginal hazard ratios","volume":"32","author":"Austin","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.jfma.2022.10.012_bib34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jfma.2022.10.012_bib35","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","article-title":"Propensity score methods for confounding control in nonexperimental research","volume":"6","author":"Brookhart","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2022.10.012_bib36","first-page":"S43","article-title":"Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer","volume":"95","author":"Quinn","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jfma.2022.10.012_bib37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2009.09.040","article-title":"Adenocarcinoma: a unique cervical cancer","volume":"116","author":"Gien","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jfma.2022.10.012_bib38","first-page":"912","article-title":"A comparison of adenocarcinoma and squamous cell carcinoma of the cervix","volume":"77","author":"Hopkins","year":"1991","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jfma.2022.10.012_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1006\/gyno.1995.1265","article-title":"Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma","volume":"59","author":"Eifel","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jfma.2022.10.012_bib40","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2014.08.018","article-title":"Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation","volume":"135","author":"Rose","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jfma.2022.10.012_bib41","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3802\/jgo.2017.28.e81","article-title":"Early-stage node negative cervical adenocarcinoma and squamous cell carcinoma show similar outcomes after hysterectomy: a population-based study","volume":"28","author":"Wu","year":"2017","journal-title":"J Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.012_bib42","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ijrobp.2011.12.013","article-title":"Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy","volume":"84","author":"Huang","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.012_bib43","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.3802\/jgo.2020.31.e16","article-title":"Completion hysterectomy after chemoradiotherapy for locally advanced adeno-type cervical carcinoma: updated survival outcomes and experience in post radiation surgery","volume":"31","author":"Yang","year":"2020","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.jfma.2022.10.012_bib44","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/j.ejca.2012.03.015","article-title":"Matched-case comparison of neoadjuvant chemotherapy in patients with FIGO stage IB1-IIB cervical cancer to establish selection criteria","volume":"48","author":"Hu","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jfma.2022.10.012_bib45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ygyno.2012.01.033","article-title":"Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma","volume":"125","author":"Tang","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jfma.2022.10.012_bib46","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.2021.39.15_suppl.LBA3","article-title":"Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: the randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274)","volume":"39","author":"Mileshkin","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2022.10.012_bib47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2013.10.022","article-title":"Rtog 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma","volume":"88","author":"Schefter","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622003965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622003965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:49:16Z","timestamp":1760539756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664622003965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0929664622003965"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2022.10.012","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term treatment outcomes\/toxicities of definite chemoradiotherapy (intensity-modulated radiation therapy) for early-stage \u201cbulky\u201d cervical cancer and survival impact of histological subtype","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2022.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}